Compare
Caris Life Sciences, Inc. vs Guardant Health, Inc. vs Veracyte, Inc. vs CareDx, Inc.
| Latest fiscal year | Caris Life Sciences, Inc. CAI | Guardant Health, Inc. GH | Veracyte, Inc. VCYT | CareDx, Inc. CDNA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $812.03M | $982.02M | $517.14M | $379.81M |
| Revenue growth (YoY) | +97.0% | +32.9% | +16.0% | +13.8% |
| Gross margin | n/a | 64.5% (computed) | 70.1% | n/a |
| Operating margin | 5.6% | -44.5% | 11.2% | -8.1% |
| Net margin | -8.4% | -42.4% | 12.8% | -5.6% |
| Net income | -$68.09M | -$416.28M | $66.35M | -$21.35M |
| EPS (Diluted) | -$3.22 | -$3.32 | $0.82 | -$0.40 |
| Operating cash flow | $83.16M | -$184.76M | $136.31M | $42.03M |
| Free cash flow | $66.89M | -$233.07M | $126.63M | n/a |
| Cash & equivalents | $796.27M | $378.20M | $362.58M | $65.43M |
| Total assets | $1.13B | $2.01B | $1.41B | $413.23M |
| Total liabilities | $548.36M | $2.11B | $96.44M | $110.13M |
| Shareholders' equity | $577.31M | -$99.31M | $1.31B | $303.10M |
| Return on year-end equity | -11.8% | n/a | 5.1% | -7.0% |
| Shares outstanding | 282.53M | 130.64M | 79.36M | 50.92M |
Revenue, most recent five fiscal years
| Fiscal year | Caris Life Sciences, Inc. | Guardant Health, Inc. | Veracyte, Inc. | CareDx, Inc. |
|---|---|---|---|---|
| Latest | $812.03M Ended 2025-12-31 | $982.02M Ended 2025-12-31 | $517.14M Ended 2025-12-31 | $379.81M Ended 2025-12-31 |
| 1 year earlier | $412.26M Ended 2024-12-31 | $739.02M Ended 2024-12-31 | $445.76M Ended 2024-12-31 | $333.79M Ended 2024-12-31 |
| 2 years earlier | $306.13M Ended 2023-12-31 | $563.95M Ended 2023-12-31 | $361.05M Ended 2023-12-31 | $280.32M Ended 2023-12-31 |
| 3 years earlier | n/a | $449.54M Ended 2022-12-31 | $296.54M Ended 2022-12-31 | $321.79M Ended 2022-12-31 |
| 4 years earlier | n/a | $373.65M Ended 2021-12-31 | $219.51M Ended 2021-12-31 | $296.40M Ended 2021-12-31 |